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The effect of newer antiarrhythmic drugs on defibrillation
threshold
W. A. TACKER, MD, PhD; M. J. NIEBAUER, MS; C. F. BABBS, MD, PhD; W. J. COMBS;
B. M. HAHN; M. A. BARKER; J. F. SEIPEL; J. D. BOURLAND, PhD; L. A. GEDDES, PhD
Biomedical Engineering Center, Purdue University, West Lafayette, Indiana, USA

ABSTRACT
This study was conducted to determine the effects of clofilium phosphate and bretylium tosylate
on ventricular defibrillation threshold. Dogs were anesthetized with pentobarbital and subjected
to repeated fibrillation-defibrillation episodes. Defibrillation thresholds were determined at 15min intervals using underdamped 5-6 msec sinusoidal current shocks, from 30 min before drug
injection to 120 min after injection. Eight dogs were given clofilium phosphate (0.34 mg/kg, iv).
Another 10 dogs were given bretylium tosylate (10.0 mg/kg, iv). Both drugs lowered
defibrillation threshold from 15-90 min after injection. The maximum clofilium effect was a 31%
decrease in threshold current and a 54% decrease in threshold energy. The greatest decrease in
defibrillation threshold produced by bretylium was 16% for current and 31% for energy. These
drug induced changes in defibrillation threshold are of potential clinical benefit, if they occur in
human subjects at doses that are effective for control of ventricular arrhythmias.
Key words: ACD, AICD, arrhythmia, automatic implantable defibrillator-cardioverter,
defibrillation, ventricular fibrillation, sudden cardiac death

Critical Care Medicine 1980, Vol 8, Number 3, pages 177-180

Supported, in part, by a grant from Eli Lilly and Company, Indianapolis, IN.

1

INTRODUCTION
The authors have shown recently that three major antiarrhythmic drugs (quinidine, phenytoin,
and lidocaine) increase the threshold shock strength required for ventricular defibrillation in
dogs.1 This effect presents a potential clinical problem, because fibrillation may still occur after
these antifibrillatory drugs have been given, and immediate electrical defibrillation is required. In
particular, fibrillation may often occur after administration of lidocaine in the coronary care
unit.2
An experimental drug, clofilium, developed by Eli Lilly and Company, seems to be the first
member of a new class of antiarrhythmic drugs with a mechanism of action quite different from
either quinidine, phenytoin, or lidocaine. This new compound probably blocks outward
potassium current through the cell membrane and has been shown to produce chemical
defibrillation in the absence of a defibrillator countershock.3 Such spontaneous defibrillation is
tantamount to decreasing electrical defibrillation threshold to zero.
Bretylium tosylate has recently been approved for use as an antiarrhythmic in the United States
and also has different pharmacological properties than the drugs mentioned previously.4
Bretylium, like clofilium, has been reported to produce chemical defibrillation in the absence of
a defibrillator countershock.5 Because of the apparent ability of these two agents to make
defibrillation easier, and because of their unique pharmacological characteristics, the authors
have investigated the effects of intravenous clofilium phosphate and bretylium tosylate on
ventricular defibrillation threshold in dogs.
METHODS
Eighteen mongrel dogs weighing from 9 to 22 kg were studied. Each dog was anesthetized with
pentobarbital sodium (30 mg/kg, iv) and intubated to maintain a patent airway. Pentobarbital
anesthesia was selected because it does not itself alter the defibrillation thresh- old. 6 Lead II ECG
was monitored using subdermal pin electrodes. A femoral vein was catheterized for
administration of additional doses of pentobarbital to maintain anesthesia, as well as for
administration of the antiarrhythmic drugs. A femoral artery was catheterized for direct
measurement of blood pressure. A bipolar stimulating electrode mounted on a catheter was
passed from the right jugular vein into the right ventricle to initiate fibrillation. Low resistance
electrolytic gel and 10-cm diameter electrodes for external defibrillation were applied to the
shaved right and left chest walls and the electrodes sutured in place. The defibrillator used in this
study produced a slightly underdamped sinusoidal current waveform.7 The duration of the
current pulse was maintained between 5-6 msec for each dog by varying the capacitance of the
defibrillator from 20-40 microfarads. The inductance was set at 63 millihenrys, and the internal
resistance of the defibrillator was 3.5 ohms. Voltage and current were displayed on a dual trace
storage oscilloscope (Tectronix Inc., Beaverton, OR). The apparent impedance of the chest was
calculated as the ratio of peak voltage to peak current. Stored energy, Ws, was calculated from
the capacitance and initial voltage on the capacitor as;
Ws = (1/2)CE2
2

where; C = capacitance, and E = voltage applied to the capacitor. Delivered energy was
calculated using the equation
Wd = Ws[Za/(Za + Ri)]
where Wd = delivered energy, Ws = stored energy, R i = internal resistance of the defibrillator,
Za = apparent impedance of the subject.
Ventricular fibrillation was produced by 60 Hz electrical stimulation through the transjugular
stimulating electrode, and confirmed by the ECG and by the loss of arterial blood pressure
pulses. Test shocks from the defibrillator were delivered at end-expiration and within 30 sec of
the onset of ventricular fibrillation. If the test shock failed to defibrillate, a backup shock of
approximately 2 amp/kg body weight was applied to achieve defibrillation. Following
defibrillation, blood pressure was allowed to return to prefibrillation levels before the next
fibrillation-defibrillation trial. A defibrillation threshold value was defined as a current intensity
which defibrillated, but was no more than 10% greater than a current that did not defibrillate.
Only test shocks (and not backup shocks) were used to establish threshold values.
Defibrillation threshold values were determined at 15-min intervals for 30 min before and 120
min after administration of test drugs. After measurement of three predrug thresholds, 0.34
mg/kg (1.0 mole/kg) clofilium phosphate (Eli Lilly and Co.) was administered to 8 dogs as an
intravenous bolus via the femoral vein. Similarly, in another 10 dogs 10.0 mg/kg bretylium
tosylate (Bretylol; Arnar-Stone Laboratories Inc.) was administered as an intravenous bolus and
defibrillation threshold was monitored. These doses were selected because they are effective in
preventing ventricular fibrillation in dogs. The three predrug threshold determinations for each
dog were averaged and the mean values equated to 100% of control for each dog. Individual
postdrug values were expressed relative to these predrug control values. The resulting
normalized data from all of the animals were then averaged and the Mann-Whitney statistic
calculated to test the null hypothesis that the various postdrug thresholds were the same as the
predrug control thresholds.
RESULTS
Clofilium phosphate and bretylium tosylate clearly depressed the current (Figs. 1A and 1B) and
energy (Figs. 2A and 2B) thresholds for ventricular defibrillation when given before the onset of
fibrillation. Energy requirements for defibrillation dropped 54% after clofilium and 31% after
bretylium. The onset of action was rapid with both drugs, producing near maximal depression of
threshold 15 min after injection. In addition to the effect upon threshold, the authors observed
that in some subjects that the time required for blood pressure to recover was prolonged after
administration of bretylium. After clofilium administration, the authors did not observe slow
blood pressure recovery after defibrillation.
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FIG. 1. A. Effect of
intravenous clofilium
phosphate (0.34 mg/kg, given
at t = 0) on current threshold
for ventricular defibrillation in
8 dogs (mean ± SEM). The
absolute current threshold
value corresponding to 1.00 on
the vertical axis was 1.15
A/kg. All threshold
depressions after drug injection
are statistically significant (U
< 25. p < 0.001). Because of
the difference in the standard
deviations of predrug and
postdrug data, the MannWhitney U-test of significance
was used to compare postdrug
values with the predrug values
in this and subsequent figures.
B. Effect of intravenous
bretylium tosylate (10.0
mg/kg, given at t = 0) on
current threshold for
ventricular defibrillation in 10
dogs (mean ± SEM). The
absolute current threshold
value corresponding to 1.00 on
the vertical axis was 0.97
A/kg. All threshold
depressions after bretylium
injection are statistically
significant (U < 93, p < 0.05)
except the data point at 90 min
postinjection.
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FIG. 2. A. Effect of intravenous
clofilium phosphate (0.34 mg/kg.
given at t = 0) on energy threshold
for ventricular defibrillation in 8
dogs (mean ± SEM). The absolute
threshold value corresponding to
1.00 on the vertical axis was 2.59
J/kg. All threshold depressions
after drug injection are statistically
significant (U < 18, p < 0.0003 ).
B. Effect of intravenous bretylium
tosylate (10.0 mg/kg, given at t =
0) on energy threshold for
ventricular defibrillation in 10 dogs
(mean ± SEM). The absolute
threshold value corresponding to
1.00 on the vertical axis was 1.77
J/kg. All threshold depressions
after bretylium injection are
statistically significant (U < 75.
p < 0.01).
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DISCUSSION
This report is the first to describe depression of defibrillation threshold by antiarrhythmic drugs.
This effect is in direct contrast to the effects of quinidine, phenytoin, and lidocaine, all of which
increase defibrillation threshold when given before the onset of fibrillation. 1 The apparent
advantage of bretylium to decrease defibrillation threshold must be balanced against the apparent
loss of hemodynamic recovery that we observed after it was given. Bretylium possesses
antiadrenergic and hypotensive actions associated with depletion of norepinephrine from
peripheral adrenergic nerve endings.4 In accordance with this known mechanism, some subjects
treated with bretylium may not be able to recover as well from fibrillation-defibrillation episodes
because of less effective autonomic reflexes. In a clinical study, however, Haynes et al.8 found
no differences in resuscitative results (short term or long term survival) for patients after use of
bretylium as compared to lidocaine.
The 0.34 mg/kg dose of clofilium decreased the energy threshold for defibrillation by 50%, but
did not seem to adversely affect cardiovascular function. To the knowledge of the authors, this
ability to depress defibrillation threshold without toxic side-effects is a unique property of
clofilium. The digitalis glycoside, ouabain, may produce a similar (up to 50%) depression of
defibrillation threshold,9 but only at doses approaching the LD50. Likewise, profound
hyperkalemia (8-13 mEq/liter) can depress defibrillation threshold,10 but only in conjunction
with severe cardiac dysrhythmias and weakening of cardiac contractility.
The elevation of defibrillation threshold by standard antiarrhythmic drugs1 may explain, in part,
the lower defibrillation success rate for in-hospital versus out-of-hospital patients.11-15 The
contrasting depression of defibrillation threshold by the newer antiarrhythmc drugs in this study
may be of clinical benefit if it occurs in human subjects at doses that are effective for control of
ventricular arrhythmias.
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